Us Bancorp \De\ Allovir, Inc. Transaction History

Us Bancorp \De\

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 03, 2023	BUY	$2.15 - $3.64 $950 - $1,608	442 New	442 $0
Q1 2022 May 11, 2022	SELL	$6.75 - $13.52 $587 - $1,176	-87 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$12.94 - $25.99 $2,070 - $4,158	-160 Reduced 64.78%	87 $1,000
Q3 2021 Nov 10, 2021	BUY	$16.97 - $25.06 $1,476 - $2,180	87 Added 54.37%	247 $6,000
Q2 2021 Aug 05, 2021	BUY	$19.44 - $25.06 $3,110 - $4,009	160 New	160 $3,000

44.4M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $933M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.